What You Should Know
- The cancer drug Sacituzumab tirumotecan, or sac-TMT, helped women with advanced or recurrent endometrial cancer live a median of 19 months, compared with 12.1 months with standard chemotherapy.
- It also delayed cancer growth: median progression-free survival was 7.2 months with sac-TMT versus 3.9 months with chemotherapy.
- Sac-TMT is not yet FDA-approved for endometrial cancer, and side effects—including low blood counts, mouth sores, and eye problems—will be an important part of treatment decisions.
Patients who received sacituzumab tirumotecan, also called sac-TMT (and MK-2870), lived a median of 19 months after entering the study. Those treated with standard chemotherapy lived a median of 12.1 months. That difference, nearly seven months, is meaningful in a setting where effective treatments have been limited.
Read MoreWhat Is Sac-TMT?
Sac-TMT is an antibody-drug conjugate, or ADC. An ADC combines two parts:- An antibody designed to find a protein on cancer cells
- A cancer-killing drug attached to that antibody
What Did the Study Find?
TroFuse-005 included 776 women with advanced or recurrent endometrial cancer. Everyone had already received platinum chemotherapy (a common type of chemo that includes drugs such as carboplatin) and a type of immunotherapy called a PD-1 or PD-L1 inhibitor. Patients had received no more than three previous treatment regimens.
They were randomly assigned to receive either sac-TMT every two weeks or one of two commonly used chemotherapy drugs, doxorubicin or paclitaxel.
The study measured several outcomes:
- Overall survival (OS): how long patients lived after joining the study. Median OS was 19 months with sac-TMT and 12.1 months with chemotherapy. “Median” means half the patients lived longer and half lived for a shorter time. It does not predict how long one person will live.
- Progression-free survival, or PFS: How long patients lived without the cancer growing, spreading or causing death. Median PFS was 7.2 months with sac-TMT and 3.9 months with chemotherapy.
- Response rate: The percentage of patients whose tumors became smaller or disappeared on scans. This happened in 35.1% of patients receiving sac-TMT and 17.3% receiving chemotherapy.
Put another way, sac-TMT lowered the risk of death by 32% and the risk of cancer progression or death by 41% during the study period. These percentages describe differences between the two groups. They do not predict how an individual patient will do.
What Could This Mean for Patients?
If sac-TMT is approved, it could give doctors another option after platinum chemotherapy and immunotherapy stop controlling the cancer. It would not be a treatment for every person with endometrial cancer.
Dr. Sarah Lynam, a gynecologic oncologist at UH Seidman Cancer Center, said the treatment added: “almost 7 months of longevity to a population with historically poor prognosis.”
Dr. David G. Mutch, Professor of Obstetrics and Gynecology at WashU Medicine at the Siteman Cancer Center, called the findings a significant advance for patients previously treated with platinum chemotherapy and immunotherapy. In his view, sac-TMT “should be another treatment option in women who, heretofore, had none.”
There is still an important tradeoff: more time does not automatically mean easier treatment.
What About Side Effects?
Almost everyone in both groups had at least one treatment-related side effect. Serious, or grade 3 and higher, side effects occurred in 54.4% of patients receiving sac-TMT and 41.4% receiving chemotherapy.
The more common problems with sac-TMT included:
- Anemia, meaning too few red blood cells
- Neutropenia, meaning low levels of infection-fighting white blood cells
- Painful sores or inflammation in the mouth
- Dry, irritated, or itchy eyes
Only 3.1% of patients stopped sac-TMT because of a treatment-related side effect. Overall quality-of-life scores were maintained during the study, although individual experiences can vary.
Dr. Lynam said these findings show why doctors must consider “quantity as well as quality of life” when treating recurrent gynecologic cancers.
Questions to Ask Your Doctor
- Have I already received the treatments required before sac-TMT could be considered?
- Is sac-TMT available to me through a clinical trial or another access program?
- How might its possible benefits apply to my type of endometrial cancer?
- How would my blood counts, mouth, and eyes be monitored?
- What other treatments remain reasonable for me?
Learn more about SurvivorNet's rigorous medical review process.

